● TIER 1 — FDA-approved / recognizedGRADE AMetabolic (other)
Vosoritide
CNP analog. Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database.
FDA status
Approved: Voxzogo.
Compounding (503A/503B)
Approved.
DEA
Not controlled.
WADA (sport)
Not listed on 2026 Prohibited List (no matching section found)
Mechanism
NPR-B agonist.
Human evidence · 1
Phase 3, n=121 children with achondroplasia. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
Reference only. This page summarizes publicly available regulatory and research information about Vosoritide. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.